Corresponding with IFN-γ expression, the frequency of T-bet+ T cells was elevated during DSS colitis, which—especially in CD4+ T cells—could be limited by the late administration of tofacitinib medication (Figure 5C). The gene discussed is CD4; the disease is colitis.